Generation-HD1 Study Open at Leeds CRF, UK First Patient Enrolled

Wednesday 28th August 2019

Last month LTHT became the first site in the UK to enrol a patient onto the Generation-HD1 study to evaluate the efficacy of a new drug in patients with manifest Huntington's Disease.  Participants will have either the trial drug or a placebo administered into their spinal fluid after undergoing lumbar punctures.

The Phase III study, sponsored by Roche and taking place at 11 sites in the UK, is being co-ordinated by the LTHT Clinical Genetics team, with Dr Jeremy Cosgrove as Principal Investigator.  Participants will be receiving the drug infusion within the Leeds Cardiovascular Clinical Research Facility at Leeds General Infirmary (LGI), as well as clinical tests including ECG and blood testing.  We are hoping to enrol a minimum of 4 patients at LTHT, out of 660 worldwide.

Huntington's is a rare genetic condition for which there is currently no cure, which causes the brain's nerve cells to break down, severely impairing mobility and brain function over time. It affects 1 in 10,000 people. To find out more information, visit

M20190712 016 Group shot Medical trial caser study LG7 5472 opt